

August 2017



Disclaimer

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. pricing and product initiatives of competitors;
2. legislative and regulatory developments and economic conditions;
3. delay or inability in obtaining regulatory approvals or bringing products to market;
4. fluctuations in currency exchange rates and general financial market conditions;
5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6. increased government pricing pressures;
7. interruptions in production;
8. loss or inability to obtain adequate protection for intellectual property rights;
9. litigation;
10. loss of key executives or other employees; and
11. adverse publicity and news coverage.

There can be no assurance that any existing or future regulatory filings will satisfy any health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Medical Development International Limited is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Any statements regarding earnings is not a profit forecast and should not be interpreted to mean that Medical Developments International's earnings for this year or any subsequent period will necessarily match or exceed the historical published earnings of Medical Developments International. Medical Developments International Limited, its directors, officers and employees do not accept any liability whatsoever for any damage or loss caused by anything contained in this document.

For marketed products discussed in this presentation, please see full prescribing information on our website at www.medicaldev.com

All mentioned trademarks are legally protected.

Vision

Medical Developments International (MVP) is a leading Emergency Medicine Company.

Our aim is to:

1. Provide unique and innovative products to assist our customers in the management of acute pain, trauma and procedural pain and to be the market leader globally.
2. Provide unique and innovative products to assist our customers in the management of delivery of respiratory medications, resuscitation and oxygen therapies and to be the market leader in Medical Devices for Asthma and COPD markets globally.

Penthrox[®]

Penthrox®

UK and Ireland update

In market sales in the UK and Ireland grew 167% in H2FY17.

There are 56 hospital formulary approvals.


All 56 hospitals are ordering on a regular basis.

Penthrox has been sold into 122 Hospitals, clinics and ambulance services in the UK and Ireland so far.

Many of these first sales are “pre formulary” approvals.

20+ additional formulary approvals are expected in the next few months, including Kings College.

In market sales into hospitals are growing at a rate of 20+% a month for the last 6 months.




Penthrox®

France update

We are delighted by our partner's progress in France.

In market sales in France are growing quickly. In summary:

- The target is 350 hospitals to approve Penthrox in France.
- 250 formulary applications have already been submitted.
- 99 formularies have approved Penthrox in France.
- 21 formularies have rejected the formulary applications.
- 143 hospitals have ordered Penthrox in France.
- About 50% of customers who have ordered Penthrox have already re-ordered.




Regulatory approval for Penthrox in the rest of Europe

We are ahead of our timeline for Penthrox to be approved in another 22 European countries.

Sales are expected during H2FY18.

We expect Regulatory Approvals for an additional 15 countries during 2018.



Czech Republic	Portugal
Poland	Spain
Slovakia	Saudi Arabia
Macedonia	Hong Kong
Albania	Jordan
Montenegro	Iraq
Kosovo	Canada
Slovenia	Austria
Croatia	South Korea
Serbia	Netherlands
Greece	Denmark
Malta	Luxembourg
Norway	Liechtenstein
Andorra	Monaco
Italy	San Marino
Germany	Bosnia
Sweden	Vatican City
Switzerland	Herzegovina
Mexico	

Penthrox®



Australia and New Zealand

Sales of Penthrox to Ambulance in Australia remain strong.

Sales of Penthrox to Hospitals grew 20%.

Sales of Penthrox to GP's grew 21%.

Sales of Penthrox to NZ Ambulance grew 593% as a result of all NZ Ambulances adopting Penthrox as first line sole analgesia in all ambulances.



Penthrox®

USA

Work on getting Penthrox approved in the USA is progressing well.

We are on track to submit our IND in the next six months.

After discussions with the FDA we will request Penthrox be granted “fast track” status by the FDA.

We are very encouraged by our recent FDA meeting.

We believe the aggressive negative bias against opioids for analgesia in the USA make Penthrox a compelling alternative.

The Washington Times

Trump directs administration to treat opioid crisis as a ‘national emergency’

The New York Times

Inside a Killer Drug Epidemic: A Look at America's Opioid Crisis

The opioid epidemic killed more than 33,000 people in 2015. What follows are stories of a national affliction that has swept the country, from cities on the West Coast to bedroom communities in the Northeast.


JUNE 6, 2017

The Washington Post

Trump says opioid crisis is a national emergency, pledges more money and attention

Los Angeles Times

The U.S. should rethink its entire approach to painkillers and the people addicted to them, panel urges



In 2015, 2 million Americans were thought to be abusing prescription narcotics.

The report said some who are dependent on painkillers will turn to street drugs such as heroin and cocaine. (July 14, 2017)

The New York Times

Drug Deaths in America Are Rising Faster Than Ever


By JOSH KATZ JUNE 5, 2017

New data compiled from hundreds of health agencies reveals the extent of the drug overdose epidemic last year.

AKRON, Ohio — Drug overdose deaths in 2016 most likely exceeded 59,000, the largest annual jump ever recorded in the United States, according to preliminary data compiled by The New York Times.

Future of Penthrox®

Penthrox® clinical program for USA



Future of Penthrox®

Global growth plans



Future of Pentrox®

Clinical development program

Additional clinical trials and studies are planned for FY18 (and beyond) which will broaden the indications for use of Pentrox®. Our longer term ambition is to extend the use of Pentrox® into:

- Acute Pain / Minor Surgical Procedures (market size estimate \$2billion);
- Acute Anxiety – replacement therapy for SSRI's or Benzo's;
- Breakthrough Pain / Repeat Use (market size estimate \$6billion); and ultimately
- Home Use / First aid box.

Future of Pentrox®

Clinical development program

A summary of clinical trials and studies underway (including in planning stage) which are designed to gain regulatory approvals around the world and extend the approved “indications of use” for Pentrox:

- Paediatric study for Pentrox in Europe. This will be used to gather additional approvals around the world.
- Head to head study Pentrox v Standard of care in the ER (including opioids-Italy). Global application.
- Head to head study Pentrox v Standard of care in the ER (including opioids-Spain). Global application.
- Nurse Initiated Pain Protocol with Self-Administered Inhaled Analgesia in the Emergency Department (Sing Health).
- A Post Authorisation Safety Study for the users of Pentrox in Europe. Global application – particularly USA.
- Animal studies covering toxicity, repeat use and pharmacokinetics (USA).
- 2 x Healthy Volunteer studies (USA and Europe). Designed for USA approval and global indication extensions.
- Truss Biopsy in Australia (to promote use of Pentrox in minor surgical procedures).
- Pentrox in Acute Pain – colonoscopy (Europe). To extend the indication in Europe and elsewhere to Acute Pain Procedures.

Future of Pentrox[®]

New manufacturing technology

Our new manufacturing facility has been completed on time and on budget.

TGA is scheduled to return and audit the facility during September.

We expect to be fully GMP compliant by the end of 2017.

The new facility will deliver a quantum shift in the manufacturing of Pentrox in terms of cost, quality, consistence and capacity.



Future of MVP

New manufacturing technology

Our Process Development Project (PDP) with the CSIRO is progressing very well. Our ambition is to develop new manufacturing technologies that will deliver cost saving, improved quality, consistency and safety standards for existing and new small molecule pharmaceuticals.

We have successfully completed 'desk top' scientific due diligence on 3 molecules which relate to the following markets:-

- A non steroidal anti-inflammatory drug: Est. \$5 billion market size
- A bronchodilator/chronic respiratory drug: Est. \$100 million market size
- A non-opiate analgesic for localised pain relief: Est. \$3 billion market size

Work continues.




Future of MVP

New manufacturing technology

We have successfully invented a process to manufacture a small molecule pharmaceutical where the raw material is usually purchased at Reaction Step 4.

We are investigating ways we can make the raw material at Reaction Step 4 using our technology (i.e. Reaction Step 1 to 4).

If so, the result could be that this small molecule will be manufactured at a fraction of the price the world currently makes it at.



Future of MVP

Intellectual Property

MVP is protecting its future by generating intellectual property from its manufacturing technology and delivery devices.

MVP has filed and is managing the following patents and trademarks:

- 6 Pentrox Inhaler patents;
- 1 manufacturing patent; and
- numerous trademark filings to mirror global growth.

MVP is also generating significant “Data Exclusivity” rights from its successful regulatory approvals around the world.

Note: “Data Exclusivity” works like a patent and protects the product in market from competition but usually for a shorter period of time.

Penthrox®

Outlook

MVP's ambition is to globalise Penthrox and in doing so make it the main stream analgesic of choice around the world. That process has begun. Over the next 12 months+ we expect to:

1. obtain approval to sell Penthrox in 37 countries throughout Europe and in a number of countries outside the EU. We expect to make first sales during H2FY18 into many of these new countries. However we expect more material sales growth to commence during FY19 and beyond as the various approvals at hospital level are obtained and the use of Penthrox becomes “main stream”.
2. conclude additional distribution partnership for new countries;
3. commence and progress work on gathering the clinical data needed to submit a “New Drug Application” to the Food & Drug Administration in the USA, and extend the ‘indications for use’ for Penthrox; and
4. continue work to develop a new manufacturing process for small molecule pharmaceuticals and create significant intellectual property.

Respiratory and Medical Devices

MVP Medical

Respiratory Division

Sales of Respiratory Devices across the world grew 50%



Sales of Respiratory Devices in the USA grew 353%

We now have almost 11,000 pharmacies available to sell our product across the USA

Sales of Respiratory Devices in Europe grew 32%


Sales of Breath-A-Tech in Australia grew 182%

Sales of Medical Devices globally (including VET) grew 45%



Respiratory Devices

Sold in 20 countries



Respiratory Devices

USA

We have access to 11,000 pharmacies in the USA

We are core range for Walmart, Sam's, Kmart and others

There are 67,000 pharmacies in the USA

The response to our product offering in the USA has been excellent

We are working on additional pharmacy chain deals

We are now adding focus to GPO Hospital contracts

We expect excellent sales growth to be generated from the USA



Respiratory Devices

Intellectual Property

MVP is protecting its future by generating intellectual property from its new range of respiratory devices.

MVP has filed a number of global patents.

MVP has filed international Trade Marks and Registered Designs in more than 20 countries.

Respiratory Devices

Outlook

MVP's ambition is to globalise the sales of its Respiratory Devices. That process has begun. We already have partners and make sales in more than 20 countries.

Over the next 12 months we expect to:



1. obtain additional partnership deals in the USA and deliver sales growth;
2. obtain additional partnership deals in other countries around the world;
3. consolidate our position as the largest supplier of Respiratory Devices in Australia;
4. introduce new products; and
5. continue to drive down costs and increase the range and quality of our products.

MVP Corporate

Financial Summary

During the year MVP:

- Delivered gross sales of \$18.9m up 22%
- Delivered Net Profit after tax of \$1.82million up 16%
- Incurred \$550K of “one off” expenses
- Reinvested profits, upfronts and milestones back into the business to facilitate global growth
- Paid 4 cent fully franked dividends



Financial Summary

MVP:

- Recently secured a Debt Funding facility of \$11m which will be used to fund future development projects
- Received \$7.3m in upfront and milestone payments from partners
- Invested:
 - \$4.3m into the new manufacturing facility,
 - \$4.3m into clinical trials and Pentrox regulatory approvals
 - \$1.2m in dividends

MDI Investor Dashboard (ASX: MVP)

Historical Stock Chart (3yr)



Current Stock Price

5.14 ↓ 0.010 (0.19%)
16 Aug, 3:26pm

Day High 5.150

Day Low 5.090

Open 5.150

Prev. Close 5.150

Avg. Volume 13,332

52 Wk. High 5.990 (16 Aug 2016)

52 Wk. Low 4.120 (6 Dec 2016)

Mkt. Cap 300.18 (Mil)

MVP Corporate Overview

David Williams



Non-Executive Chairman

The Managing Director of Kidder Williams Ltd, with 32 years experience in investment banking.

Dr Harry Oxer



Non-Executive Director

A Medical Consultant to MVP and St John Ambulance in Western Australia.

Leon Hoare



Non-Executive Director

Recent Managing Director of Smith & Nephew in Australia and New Zealand.

Max Johnston



Non-Executive Director

Former MD of J&J Pacific. Non-Executive Director of Polynovo Limited and Former Chairman of Probiotec Limited.

Allan McCallum



Non-Executive Director

Over 20 years public companies experience including an ASX 50 company.

Phillip Powell



Non-Executive Director

A Chartered Accountant and has an extensive finance background.

John Sharman



Chief Executive Officer

Mark Edwards



Group Financial Controller & Company Secretary

Glenn Gilbert



Head, Sales & Marketing

Scott Courtney



Director of Operations & Research

Maggie Oh



Director of Scientific Affairs

Jake Golding



Quality Assurance & Validation Manager

MVP Global Strategy

**New and revised
materials and process**

(lowest cost producer and
significant IP)

Product innovation

(world's best manufacturing
processes and delivery
devices resulting in significant IP)

**New
Business
Partners**

Clinical trials

(Commercial clinical studies
to support marketing and
product development)

**Regulatory
Approval and
new markets**



Contact Details

HEAD OFFICE

4 Caribbean Drive

Scoresby, Victoria, Australia, 3179

Tel: +61 3 9547 1888

Fax: +61 3 9547 0262

Web: www.medicaldev.com

